{"id":"W3130005770","doi":"10.1007/s10549-021-06109-7","title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Institute for Health and Care Research; Pfizer","keywords":"Trastuzumab; Medicine; Enzalutamide; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Response Evaluation Criteria in Solid Tumors; Regimen; Adverse effect; Androgen receptor; Cancer; Clinical endpoint; Progressive disease; Phases of clinical research; Prostate cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003523798,0.0002887108,0.0005515331,0.000138648,0.0002750452,0.00007112079,0.00008369813,0.0000526826,0.0001555731],"category_scores_gemma":[0.00003438877,0.0001482938,0.00002628795,0.000683034,0.000856043,0.0001187713,0.000102738,0.0003147403,0.000001174951],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009829615,"about_ca_system_score_gemma":0.002115119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0046853,"about_ca_topic_score_gemma":0.01277301,"domain_scores_codex":[0.9970912,0.0002903076,0.0003069641,0.0006464492,0.0009459227,0.0007191133],"domain_scores_gemma":[0.9978517,0.0005170492,0.00007376044,0.000339198,0.0007718566,0.0004464454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.07005524,0.001216314,0.4242245,0.0002684258,0.0009932894,0.000279646,0.0008816873,0.00002284894,0.0002243768,0.0000495072,0.00004097459,0.5017433],"study_design_scores_gemma":[0.02603163,0.00580888,0.9616592,0.001927757,0.0001358946,0.0003500019,0.00108957,0.00002768815,0.002084584,0.00001644297,0.0006649951,0.0002033442],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872134,0.00617546,0.000005824814,0.003389611,0.00001720221,0.001964381,0.001097,0.00001114192,0.0001259687],"genre_scores_gemma":[0.985625,0.01282682,0.0002395371,0.00003909526,0.0000386683,0.0006612039,0.00004194065,0.00004839066,0.0004793345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5374348,"threshold_uncertainty_score":0.7127638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02784040980921412,"score_gpt":0.3571205290673999,"score_spread":0.3292801192581858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}